EcoDrugPlus

Plasminogen Activator, Tissue

Ensembl ID : ENSMAMG00000014017
Gene Symbol: PLAT
2 Cross references
205 Possible Orthologues:

Platelet-Activating Factor Receptor-Like

Ensembl ID : ENSMAMG00000026499
Gene Symbol: LOC113130623
2 Cross references
223 Possible Orthologues:

Platelet-Activating Factor Receptor-Like

Ensembl ID : ENSMAMG00000026159
Gene Symbol: LOC113130613
2 Cross references
223 Possible Orthologues:

Platelet-Derived Growth Factor Beta Polypeptide B

Ensembl ID : ENSMAMG00000005518
Gene Symbol: PDGFBB
2 Cross references
196 Possible Orthologues:

Platelet-Derived Growth Factor Receptor Beta-Like

Ensembl ID : ENSMAMG00000012776
Gene Symbol: LOC113132350
2 Cross references
174 Possible Orthologues:

Platelet-Derived Growth Factor Receptor, Alpha Polypeptide

Ensembl ID : ENSMAMG00000014846
Gene Symbol: PDGFRA
3 Cross references
203 Possible Orthologues:

Platelet-Derived Growth Factor Receptor, Beta Polypeptide

Ensembl ID : ENSMAMG00000007127
Gene Symbol: PDGFRB
3 Cross references
198 Possible Orthologues:

Polo-Like Kinase 1 (Drosophila)

Ensembl ID : ENSMAMG00000007199
Gene Symbol: PLK1
3 Cross references
188 Possible Orthologues:

Polo-Like Kinase 4 (Drosophila)

Ensembl ID : ENSMAMG00000002701
Gene Symbol: PLK4
3 Cross references
215 Possible Orthologues:

Poly (Adp-Ribose) Polymerase 1

Ensembl ID : ENSMAMG00000020652
Gene Symbol: PARP1
3 Cross references
209 Possible Orthologues:

Poly (Adp-Ribose) Polymerase 2

Ensembl ID : ENSMAMG00000008233
Gene Symbol: PARP2
3 Cross references
185 Possible Orthologues:

Poly (Adp-Ribose) Polymerase Family, Member 3

Ensembl ID : ENSMAMG00000023941
Gene Symbol: PARP3
3 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).